Compare CUE & MCHX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CUE | MCHX |
|---|---|---|
| Founded | 2014 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.0M | 66.3M |
| IPO Year | 2017 | 2003 |
| Metric | CUE | MCHX |
|---|---|---|
| Price | $0.23 | $1.45 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 876.1K | 10.8K |
| Earning Date | 03-16-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $27,466,000.00 | ★ $90,291,000.00 |
| Revenue This Year | N/A | $9.12 |
| Revenue Next Year | $105.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 195.75 | N/A |
| 52 Week Low | $0.23 | $1.26 |
| 52 Week High | $1.03 | $2.30 |
| Indicator | CUE | MCHX |
|---|---|---|
| Relative Strength Index (RSI) | 34.00 | 48.04 |
| Support Level | N/A | $1.35 |
| Resistance Level | $0.35 | $1.76 |
| Average True Range (ATR) | 0.03 | 0.08 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 6.77 | 41.90 |
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
Marchex Inc provides AI-based conversational intelligence and analytics solutions that generate insights from customer communications data. The company's products support sales, marketing, and executive teams in analyzing customer interactions across communication channels and informing business decisions. It serves companies operating in business-to-business-to-consumer (B2B2C) markets across multiple industries like automotive, home services, healthcare, real estate, and advertising. The company operates in a single segment: conversational analytics and related solutions. The company generates the majority of revenue from its conversational intelligence product offerings. Geographically, it generates the maximum revenue from the United States.